• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Insulet

Insulet to offer $300m in senior convertible notes as part of private placement

November 7, 2017 By Sarah Faulkner

Insulet Omnipod

Insulet (NSDQ:PODD) said today that it plans to offer $300 million in convertible senior notes due in 2024 as part of a private placement. The Billerica, Mass.-based company is also slated to give initial purchasers an option to buy an additional $45 million in notes. Insulet said it plans to use the offering’s net proceeds for […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

Insulet raises full-year sales forecast after Street-beating Q3

November 3, 2017 By Sarah Faulkner

Insulet Omnipod

Shares in Insulet (NSDQ:PODD) soared today after the medical device maker topped sales expectations on Wall Street with its third quarter results. The Billerica, Mass-based company posted a net loss of -$2.2 million on sales of $121.8 million for the 3 months ended Sept. 30, for bottom-line growth of 38% on sales growth of 28% compared […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

Meet 5 companies developing novel drug-delivery devices

October 26, 2017 By Sarah Faulkner

At the 7th annual Partnership Opportunities in Drug Delivery event, presented by The Conference Forum, device companies gathered to tout their drug-delivery technologies and learn from each other’s mistakes and successes. Among them were needle-free injectors, patch pumps, auto-injectors and other novel delivery devices. Moderated by Pfizer‘s (NYSE:PFE) senior director of device strategy, Mathias Romacker, […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Auto-injectors, Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Becton Dickinson, Bespak, Enable Injections, Insulet, Pfizer Inc., West Pharmaceutical Services

Insulet, Dexcom partner to lure ex-Animas users

October 19, 2017 By Brad Perriello

Insulet (NSDQ:PODD) and Dexcom (NSDQ:DXCM) yesterday floated a joint promotion aimed at luring users of the Animas insulin pump after Johnson & Johnson (NYSE:JNJ) bails out of the insulin pump biz. The companies are hoping to chip off a piece of the diabetes market from Medtronic (NYSE:MDT), to which J&J has offered to help some 90,000 Animas patients transfer (J&J is also evaluating another […]

Filed Under: Diabetes, Featured, Wall Street Beat Tagged With: DexCom Inc., Insulet

Insulet shareholder sues over OmniPod Eros

October 16, 2017 By Sarah Faulkner

Insulet Omnipod

Insulet (NSDQ:PODD) shareholder Frank Carnazza filed a derivative suit against the Billerica, Mass-based company last week in a Massachusetts federal court, alleging that Insulet misrepresented the success of its OmniPod Eros roll-out in 2013, which eventually caused the shares in the company to plummet. Carnazza named a number of former and current executives in the suit, […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Legal News, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

Insulet looks to lure Animas users

October 10, 2017 By Sarah Faulkner

Insulet Omnipod

Just days after Johnson & Johnson (NYSE:JNJ) revealed that it plans to shut down its 410-worker Animas insulin pump subsidiary, Insulet (NSDQ:PODD) said it would offer existing Animas insulin pump users a free trial of the company’s Omnipod system. Insulet’s Welcome Program includes a free Omnipod tubeless insulin delivery system, built-in blood glucose meter and 30 days […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: animas, Insulet, johnsonandjohnson, Medtronic

Insulet “bets big” on Massachusetts with new manufacturing facility in Acton

September 29, 2017 By Sarah Faulkner

Insulet's new manufacturing site in Acton

Insulet (NSDQ:PODD) broke ground at its new manufacturing facility in Acton, Mass. yesterday, hosting a ceremony that featured the state’s governor, Charlie Baker, members of Baker’s administration and a young “Podder” named Lexi Bentinganan. Diagnosed at age 7 with Type I diabetes, Lexi has been using Insulet’s tubeless insulin delivery device, the Omnipod, since 2013. “It […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Insulet

Convenience, compliance & control: How Insulet is changing insulin delivery tech

September 21, 2017 By Sarah Faulkner

Insulet Omnipod

Shacey Petrovic spent nearly a decade trying to convince her diabetic father to switch to an insulin pump, rather than inject himself multiple times each day. But he was wary of the tubing and other challenges that come with constantly wearing a pump. So when Petrovic was tapped to serve as chief commercial officer at Insulet (NSDQ:PODD) in […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Amgen, Bigfoot Biomedical, Eli Lilly & Co., GlaxoSmithKline plc, Insulet, Medtronic, Ypsomed

Insulet touts real-world data for Omnipod insulin management tech

September 13, 2017 By Sarah Faulkner

Insulet Omnipod

Insulet (NSDQ:PODD) touted real-world data today for its Omnipod insulin management system at the Congress of the European Association for the Study of Diabetes. The data come from a study of nearly 39,000 patients with Type I and Type II diabetes who received insulin through the Omnipod system and had at least three months of data […]

Filed Under: Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: abbott, Insulet

Insulet breaks ground on new manufacturing plant in Mass.

August 30, 2017 By Brad Perriello

Insulet

Insulet (NSDQ:PODD) reportedly broke ground on a new manufacturing facility on a site it bought earlier this year in Acton, Mass. The $100 million, 350,000-square foot plant is being built on a 26-acre lot Billerica, Mass.-based Insulet acquired for $9.3 million in February, according to the Worcester Business Journal. Insulet uses a quarter of contract manufacturers to make […]

Filed Under: Diabetes, Wall Street Beat Tagged With: Insulet

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 20
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS